Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.

Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions

Open access
Li, Jia-Xu, Cummins, Carolyn L.·2022·Nature Reviews Endocrinology

Abstract

Glucocorticoid hormones were discovered to have use as potent anti-inflammatory and immunosuppressive therapeutics in the 1940s and their continued use and development have successfully revolutionized the management of acute and chronic inflammatory diseases. However, long-term use of glucocorticoids is severely hampered by undesirable metabolic complications, including the development of type 2 diabetes mellitus. These effects occur due to glucocorticoid receptor activation within multiple tissues, which results in inter-organ crosstalk that increases hepatic glucose production and inhibits peripheral glucose uptake. Despite the high prevalence of glucocorticoid-induced hyperglycaemia associated with their routine clinical use, treatment protocols for optimal management of the metabolic adverse effects are lacking or underutilized. The type, dose and potency of the glucocorticoid administered dictates the choice of hypoglycaemic intervention (non-insulin or insulin therapy) that should be provided to patients. The longstanding quest to identify dissociated glucocorticoid receptor agonists to separate the hyperglycaemic complications of glucocorticoids from their therapeutically beneficial anti-inflammatory effects is ongoing, with selective glucocorticoid receptor modulators in clinical testing. Promising areas of preclinical research include new mechanisms to disrupt glucocorticoid signalling in a tissue-selective manner and the identification of novel targets that can selectively dissociate the effects of glucocorticoids. These research arms share the ultimate goal of achieving the anti-inflammatory actions of glucocorticoids without the metabolic consequences. Glucocorticoid therapies are widely used to treat acute and chronic inflammatory diseases, yet these drugs induce adverse metabolic effects. This Review highlights new insights into mechanisms of glucocorticoid-induced diabetes mellitus and discusses current and future therapeutic options. Glucocorticoid drugs are widely prescribed to treat inflammatory diseases and to prevent organ transplant rejection yet they promote hyperglycaemia and diabetes mellitus. Glucocorticoid-induced hyperglycaemia manifests directly via glucocorticoid signalling in metabolic organs and tissues (liver, adipose tissue, muscle, bone and pancreatic β-cells) and indirectly via inter-organ hormone and metabolite flux. No single consensus exists with respect to optimal screening frequency for glucocorticoid-induced hyperglycaemia due to context-dependent factors, although analysis of postprandial glucose (not fasting glucose) is recommended. Hypoglycaemic agents (such as insulin sensitizers and insulin) can provide satisfactory glucose control but need to be tailored for differences in the dose and type of glucocorticoid used. Developing selective glucocorticoid modulators that dissociate the diabetogenic from the anti-inflammatory effects of glucocorticoids continues to be challenging; however, new pharmacological targets that prevent diabetogenic effects are on the horizon. Glucocorticoid drugs are widely prescribed to treat inflammatory diseases and to prevent organ transplant rejection yet they promote hyperglycaemia and diabetes mellitus. Glucocorticoid-induced hyperglycaemia manifests directly via glucocorticoid signalling in metabolic organs and tissues (liver, adipose tissue, muscle, bone and pancreatic β-cells) and indirectly via inter-organ hormone and metabolite flux. No single consensus exists with respect to optimal screening frequency for glucocorticoid-induced hyperglycaemia due to context-dependent factors, although analysis of postprandial glucose (not fasting glucose) is recommended. Hypoglycaemic agents (such as insulin sensitizers and insulin) can provide satisfactory glucose control but need to be tailored for differences in the dose and type of glucocorticoid used. Developing selective glucocorticoid modulators that dissociate the diabetogenic from the anti-inflammatory effects of glucocorticoids continues to be challenging; however, new pharmacological targets that prevent diabetogenic effects are on the horizon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-022-00683-6

Cites

223 of 223 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 223 references

Cited by

See all 257

Metadata

Authors
Li, J.-X., & Cummins, C. L.
Venue
Nature Reviews Endocrinology
Published
2022-05-18
Volume
18
Issue
9
Pages
540-557
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W4280598314
Cited by
257
References
223
FWCI
10.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. https://app.cochat.ai/papers/10.1038/s41574-022-00683-6
The paper
Li, J.-X., & Cummins, C. L. (2022). Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00683-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.